FierceBiotech wants to hear from you. Please take a few minutes to answer a short survey about corporate development trends in the life sciences industry and we'll send you a $5 Starbucks Gift Card if you're among the first 50 qualified respondents. Click here to take the survey. Sign up for our FREE newsletter for more news like this sent to your inbox! The pact comes just months ahead of Phase III data for solanezumab and bapineuzumab, two Alzheimer's drugs held by Eli Lilly ($LLY) and a consortium led by J&J ($JNJ) and Pfizer ($PFE). Those companies have been pouring huge sums into their development efforts, though analysts give the companies poor odds. In this field, even modest results in the clinic have a shot at returning megablockbuster returns."While expectations are appropriately low, commercial prospects for success rival that of the industry's largest $20 billion-plus markets, and could transform the outlook for some of the developers," notes Deutsche Bank analysts, according to Reuters' report.
No comments:
Post a Comment